Rhythm Biosciences Ltd has released a press release.
ColoSTAT commercial deployment - First physician enrolled
Filed with ASX ·
6ix hasn’t read this filing yet.
Rhythm Biosciences Limited on 6ix
Earlier from Rhythm Biosciences
- Rhythm Biosciences Signs Manufacturing Agreement
- Quarterly Activities Report and Appendix 4C
- Enhanced Genetype colorectal cancer risk test released - supports earlier disease detection and ColoSTAT® targeting
- datma and Rhythm Biosciences Announce Collaboration to Apply Federated Real-World Data to Genomic Diagnostic Development
- Rhythm Initiates Commercialisation of ColoSTAT
Later from Rhythm Biosciences
- Rhythm Bio enters ColoSTAT agreement with 4Cyte Pathology
- Half-Year Financial Report and Appendix 4D
- Trading Halt
- Exercise of RHYO Options underwritten for $4.5m to $6.0m
- RHY Executes SE Asian Genetype Distribution Agreement
Follow Rhythm Biosciences into a list and get an email when it puts out news.
Follow Rhythm Biosciences